(1) The year ended December 31, 2023 includes reversals of stock compensation expense previously recognized due to a change in probability of performance condition for certain executive's share awards ...
(1) Three months ended September 30, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance condition for certain executive's share ...
Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") continues to evaluate and monitor the evolving geopolitical conflict in the Middle East and its effect on the Company's ...
Hosted on MSN
Core Laboratories outlines Q3 2025 revenue guidance of $127.5M-$134.5M amid margin improvements and global expansion
CEO Lawrence V. Bruno highlighted that "Core continued to execute its strategic plan of technology investments targeted to both solve client problems and capitalize on Core's technical and geographic ...
due to a change in probability of performance conditions for certain executives' share awards. The year ended December 31, 2024 includes reversals of stock compensation expense previously recognized ...
(2) Includes the write-down of leasehold improvements, right of use assets and/or other assets and exit costs associated with consolidation of certain facilities. (3) Includes gain on insurance ...
HOUSTON, Feb. 4, 2026 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") reported fourth quarter 2025 revenue of $138,300,000 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results